BRAF mutation is a risk factor for disease recurrence after surgery in metastatic melanoma
The presence of the BRAF mutation was statistically significant for disease recurrence after surgery amongst patients with advanced malignant melanoma, according to a study.
In this retrospective study, data from 52 patients treated with immunotherapy and BRAF/MEK inhibitors for disseminated malignant melanoma were analyzed to determine risk factors and treatment results over a median follow-up of 31 months.
The median progression-free survival (PFS) 1 was 6 months (1-44 months). In 27 patients (52%), a second-line systemic treatment was administered. The median PFS2 was 2 months (0-27 months), and the median overall survival (OS) was 31 months (6-108 months).
Having a BRAF mutation was a statistically significant risk factor for disease recurrence after surgery.
The median PFS1 was 7 months in patients undergoing anti-BRAF/MEK therapy and 4 months in patients undergoing mono-immunotherapy.
Amongst those treated with BRAF inhibitors, the 12-month PFS1 rate was 29% and the 24-month PFS1 rate was 7%. For patients treated with mono-immunotherapy, the 12- and 24-month PFS1 rates were 13 and 0%, respectively. The type of treatment used had no effect on OS.
Reference
Szatkowska L, Sieczek J, Tekiela K, et al. Outcomes of Patients with Metastatic Melanoma-A Single-Institution Retrospective Analysis. Cancers (Basel). 2022;14(7):1672. doi: 10.3390/cancers14071672. PMID: 35406444; PMCID: PMC8997072.
